Tolerance of Olaparib in a Patient With Unresectable Serous Gynecologic Cancer and End-Stage Renal Disease

Poly (adenosine diphosphate-ribose) polymerase enzyme (PARP) inhibitors have risen in popularity for the treatment of gynecologic cancers, largely due to an expansion of applications with the discovery of more genetic mutations that manifest as homologous recombination deficiency. PARP inhibitors fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Goon, Kelsey C, Alldredge, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Obstetrics/Gynecology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119740/
https://www.ncbi.nlm.nih.gov/pubmed/37090414
http://dx.doi.org/10.7759/cureus.36505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119740/
https://www.ncbi.nlm.nih.gov/pubmed/37090414
http://dx.doi.org/10.7759/cureus.36505

Ejemplares similares